Manipulation of the gut microbiome is becoming an important way to treat immune, gastrointestinal and metabolic disease. Probiotic therapies affecting the human gut microbiome have gained regulatory approval and are now included as part of clinical guidelines for a wide range of indications. Further, there are now a number of microbiome focused companies actively developing microbiome based diagnostics, identifying uses for small molecules acting through the microbiome and developing GMO stains to affect the microbiome. The pharmaceutical, consumer health and food industries are each attracted to microbiome focused solutions to human health issues and are impressed by the opportunities brought forth by a device capable of non-invasive sampling the gut microbiome. To prove probiotic efficacy, support mechanisms of action, discover new and efficacious strains, develop new diagnostic/prognostics and ultimately to support future claims around microbiome products requires definitive information from relatively inaccessible sites within the human GI tract. This information will open the door to personalized medicine, where diagnostic analysis of the microbiome will provide invaluable information on the likelihood of responses to probiotic and drugs.
The development of Micropharma's ingestible GI sampling device helps position the company as a world leader in human microbiome research and product development. This enabling technology provides a distinct advantage through the acquisition and analysis of samples previously inaccessible, provide additional survival and mechanistic data to support the development of probiotic products and generate near-term revenue for the company through sales of research and commercial devices and out-licensing of specific aspe
|SOURCE Micropharma Limited|
Copyright©2012 PR Newswire.
All rights reserved